Literature DB >> 18472944

Possible involvement of endothelin peptides and L-arginine-nitric oxide pathway on the effect of endotoxin in the rabbit isolated perfused kidney.

K Ozsan1, R K Türker, Z S Ercan.   

Abstract

Escherichia coli endotoxin (LPS) when infused through the renal artery of the rabbit isolated perfused kidney prepared as constant pressure mode, caused a decrease in flow rate and kidney weight indicating its primary vasoconstrictor effect. This effect was predominant in kidneys from rabbits pretreated with LPS. Endothelin-1 at a concentration of 10(-10) M and big endothelin-1 at a concentration of 10(-8) M produced equal vasoconstrictor effects in kidney. Addition of endotheHn converting enzyme inhibitor, phosphoramidon, to the perfusion medium at a concentration of 10(-6) M caused a reduction in the effects of both LPS and big ET-1 without altering the vasoconstrictor effect of ETol. However, addition of methylene blue (10(-5) M), a soluble guanylate cyclase inhibitor and N(G)-nitro-L-arginine-methyl ester (10(-6) M) to the perfusion medium caused a potentiation in the vasoconstrictor effect of LPS. Indomethacin at a concentration of 10(-6) M did not alter the effect of LPS. These results were taken as evidence for the participation of endothelin peptides and the L-arginine-nitric oxide pathway in the effect ofLPS in rabbit isolated perfused kidney.

Entities:  

Year:  1994        PMID: 18472944      PMCID: PMC2367038          DOI: 10.1155/S0962935194000293

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  18 in total

1.  Possible involvement of endothelium in the responses of various vasoactive agents in rabbit isolated perfused kidney.

Authors:  Z S Ercan; A S Soydan; R K Türker
Journal:  Gen Pharmacol       Date:  1990

2.  Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 3.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

4.  Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme.

Authors:  R Ikegawa; Y Matsumura; Y Tsukahara; M Takaoka; S Morimoto
Journal:  Biochem Biophys Res Commun       Date:  1990-09-14       Impact factor: 3.575

5.  Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat.

Authors:  R G Knowles; M Salter; S L Brooks; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1990-11-15       Impact factor: 3.575

6.  Endotoxemic acute renal failure in awake rats.

Authors:  D Kikeri; J P Pennell; K H Hwang; A I Jacob; A V Richman; J J Bourgoignie
Journal:  Am J Physiol       Date:  1986-06

7.  Modification of alpha-adrenoceptor-mediated pressor responses by NG-nitro-L-arginine methyl ester and vasopressin in endotoxin-treated pithed rats.

Authors:  M O Guc; B L Furman; J R Paratt
Journal:  Eur J Pharmacol       Date:  1992-11-24       Impact factor: 4.432

8.  Conversion of big endothelin-1 to endothelin-1 by two-types of metalloproteinases of cultured porcine vascular smooth muscle cells.

Authors:  Y Matsumura; R Ikegawa; Y Tsukahara; M Takaoka; S Morimoto
Journal:  Biochem Biophys Res Commun       Date:  1991-08-15       Impact factor: 3.575

Review 9.  Endothelins.

Authors:  G M Rubanyi; L H Botelho
Journal:  FASEB J       Date:  1991-09       Impact factor: 5.191

10.  The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats.

Authors:  G A Gray; C Schott; G Julou-Schaeffer; I Fleming; J R Parratt; J C Stoclet
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.